Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.
Adjuvants, Immunologic
Animals
Antibodies, Bacterial
/ blood
Bacterial Load
Bacterial Vaccines
/ immunology
Disease Models, Animal
Escherichia coli
/ genetics
Female
Immunization
Immunoglobulin G
/ blood
Iron
/ chemistry
Lung
/ microbiology
Mice
Necrosis
Periplasm
Periplasmic Proteins
/ genetics
Pseudomonas Infections
/ immunology
Pseudomonas aeruginosa
/ immunology
Recombinant Proteins
Vaccination
Vaccines, Synthetic
BCG
HitA
Iron acquisition
Iron-binding protein
Pseudomonas aeruginosa
Vaccine
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
09
09
2018
revised:
07
04
2019
accepted:
08
04
2019
pubmed:
13
4
2019
medline:
30
7
2019
entrez:
13
4
2019
Statut:
ppublish
Résumé
Pseudomonas aeruginosa is a notorious pathogen with increasing multi-drug resistance. This situation makes it urgent to develop a prophylactic vaccine against this pathogen. Different virulence factors play a crucial role in P. aeruginosa infection. This study focused on evaluation of the iron acquisition protein HitA as a potential vaccine candidate against P. aeruginosa in a murine infection model. The recombinant ferric iron-binding periplasmic protein HitA was overexpressed in Escherichia coli and was purified using metal affinity chromatography. The purified antigen was administered to mice in combination with Bacillus Calmette-Guérin (BCG) as an adjuvant using different vaccination regimens. Serum samples were tested for IgG1, IgG2a and total IgG antibody responses which were extremely significant. Following challenge of mice with P. aeruginosa, there was a significant reduction in bacterial load in lungs of immunized mice compared to negative control mice. Opsonophagocytic assay supported the previous results. In addition, histopathological examination of livers of challenged mice showed a significant improvement difference between immunized mice and negative control mice in various histopathological parameters. Up to our knowledge, this is the first report that investigates HitA as a potential vaccine antigen. Overall, the results of this study demonstrate the protective effect of HitA recombinant protein and highlight its importance as a promising vaccine candidate against P. aeruginosa infection.
Identifiants
pubmed: 30978430
pii: S0882-4010(18)31560-2
doi: 10.1016/j.micpath.2019.04.014
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Bacterial
0
Bacterial Vaccines
0
Immunoglobulin G
0
Periplasmic Proteins
0
Recombinant Proteins
0
Vaccines, Synthetic
0
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Pagination
181-185Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.